Document is current
Any future updates will be listed below
-
Authors
Esteban-Fernández, Alberto https://orcid.org/0000-0002-3839-7336
Gómez-Otero, Inés
López-Fernández, Silvia
López-Vilella, Raquel
Pastor-Pérez, Francisco
Otero-García, Óscar
Rodríguez-Santamarta, Miguel
García-Vega, David
Fluvià, Paula
Donoso-Trenado, Víctor
Sánchez-Corral, Ester
García-Pinilla, José Manuel
Bonilla-Palomas, Juan Luis
López López, Andrea
González-Juanatey, José Ramón
Bonet, Luis Almenar
-
Funding
Funding for this research was provided by:
Sociedad Española de Cardiología (SECAINC-INV-ICC 21/003)
Novartis Pharmaceuticals Corporation
AstraZeneca España
- License Information
-
More Information
Article History
Received: 2 January 2025
Accepted: 21 April 2025
First Online: 6 May 2025
Declarations
:
: AEF has received scientific speaking fees from Novartis, Bayer and Astra Zéneca. IGO has received funding or fees from Pfizer, Novartis, Rovi, CSL Vifor, Orion, and Boheringer-Ingelheim. The other authors declare no conflict of interest with this article.
